argenx raises approximately $300.6 million in gross proceeds in a U.S. public offering
(WorldNews Netherlands)

September 19, 2018 Regulated information - Inside information argenx raises approximately $300.6 million in gross proceeds in a U.S. public offering September 18, 2018, 8:45 PM ET - September 19, 2018, 2:45 AM CEST Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the pricing of an underwritten public offering in the United States and an offering in Europe only to qualified investors (within the meaning of Directive 2003/71/EC, as amended) (the Offering) with anticipated gross proceeds...